Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

K'anne Arthur (NPI 1144663923)

Field	Value
Entity Type	Individual
Organization	K'anne Arthur
Address	3232 N Northhills Blvd
City	Fayetteville
State	AR
ZIP	72703
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 11, 2013

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

Practice revenue is concentrated in high-cost oncology biologics and immunotherapies, with the top three Medicare codes — J9271 $748.2K (24.7% of Medicare revenue), J9299 $673.4K (22.2%), and J9144 $414.7K (13.7%) — accounting for 60.6% of the provider's Medicare revenue. The code mix (checkpoint inhibitors, anti-CD38 therapy, and other specialty injectables) aligns with a hematology/oncology infusion practice that delivers complex, clinic-based systemic cancer therapies.

Total Medicare revenue is $3.2M while Total Medicaid revenue is none (no Medicaid billing on file), making this provider effectively single-payer Medicare in scale and exposure. That payer concentration means reimbursement or utilization changes from Medicare for high-cost drugs could materially affect the practice's revenue.

Competitive standing on principal drug codes is mixed: J9299 ranks #91 of 505 providers nationally (82th percentile), and J9144 ranks #163 of 615 providers (73th percentile), indicating a stronger-than-average national presence for those agents, while J9271 ranks #529 of 1841 providers (71th percentile), which is typical volume for that code. These ranks suggest the provider is a notable, but not market-dominant, participant in administering these specific oncology agents at the national level.

Several procedural codes are statistical outliers relative to national peers, signaling distinctive practice patterns: 99215 is labeled an extreme outlier (rank #579 of 145531, 100th percentile; extreme outlier), and 74178 is likewise an extreme outlier (rank #97 of 11397, 99th percentile; extreme outlier). High-volume, high-complexity E/M billing combined with unusually high CT abdomen/pelvis volume suggests the practice manages complex patients and orders substantial diagnostic imaging.

Imaging and radiopharmaceutical services form a meaningful ancillary revenue stream: 78815 generated $264.1K (8.7% of Medicare revenue) and ranks #752 of 6566 providers (89th percentile), while A9552 produced $44.5K and ranks #192 of 2411 providers (92th percentile). The presence of PET/CT and radiotracer codes alongside high-value drug administration implies either on-site or closely affiliated imaging capacity that supports oncology staging and monitoring.

Infusion and supportive care services are evident through chemotherapeutic administration and biologic support codes: 96413 (chemotherapy administration) produced $48.3K and ranks #522 of 7514 providers (93th percentile), J1561 (immune globulin) produced $265.2K (8.8% of Medicare revenue) and ranks #52 of 180 providers (72th percentile), and J0897 (denosumab) contributed $106.9K. These lines indicate integrated infusion services and management of treatment-related supportive needs as part of the practice offering.

Laboratory testing appears to be a routine internal or closely coordinated service set, with 80053 CMPs ($18.9K, rank #671 of 26416 providers, 97th percentile), 85025 CBCs ($17K, rank #918 of 32833, 97th percentile), and 83735 magnesium ($12.9K, rank #224 of 6938, 97th percentile) all showing high percentile ranks. Consistently high national percentiles for multiple basic lab panels are consistent with ongoing monitoring of oncology patients receiving systemic therapies.

Provider tenure is well established: NPI enumerated 2013-04-11 (~13 years ago), and the lifetime Medicare revenue of $3.2M indicates a sustained, mid-sized Medicare-focused oncology practice. Combined with the code mix and percentile profile, the data describe an experienced hematology & oncology physician operating a clinic with substantial infusion, imaging, and diagnostic support services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

113 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	17,400	$40	$748.2K
J9299	Injection, nivolumab, 1 mg	28,060	$20	$673.4K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	11,520	$40	$414.7K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	6,980	$40	$265.2K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	260	$1,010	$264.1K
J0897	Injection, denosumab, 1 mg	5,940	$20	$106.9K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	3,020	$30	$102.7K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	780	$130	$98.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	560	$90	$48.3K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	290	$160	$44.5K

Showing 1–10 of 113

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 113 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

K'anne Arthur — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

113 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	26	40	20,700	$40	$896.3K
J9299	5	30	15,660	$20	$432.9K
J9144	5	10	10,530	$40	$361.9K
J1561	5	10	5,930	$40	$216.4K
Q5115	9	20	2,800	$30	$95.9K
J0897	43	160	2,580	$20	$89.7K
78815	20	100	90	$550	$83.7K
J0885	38	40	4,070	$10	$38K
96413	29	80	380	$90	$36.6K
A9552	11	40	180	$150	$28.9K

Showing 1–10 of 113

Related Providers

Other providers that share a Tax Identification Number (TIN) with K'anne Arthur, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Shore Hematology Oncology Associates PC	NY	Specialist	$0	$61.9M
Highlands Oncology Group PA	AR	Hematology & Oncology Physician	$0	$5.7M
Matthew Lockwood	AR	Hematology & Oncology Physician	$4.2M	$0
Eric Schaefer	AR	Hematology & Oncology Physician	$3.6M	$0
Patrick Travis	AR	Hematology & Oncology Physician	$3.3M	$0
Gregory Oakhill	AR	Hematology & Oncology Physician	$2.8M	$0
Stephan Rosenfeld	AR	Hematology & Oncology Physician	$2.3M	$0
J Beck	AR	Hematology & Oncology Physician	$2.2M	$0
Dmitriy Zak	AR	Hematology & Oncology Physician	$2.2M	$0
Mitchell Ross	AR	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as K'anne Arthur, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sanders, Tompkins, Schiro, Landers And Sanders PLLC	AR	Pediatric Dentistry	$0	$30.4M
Children's Therapy Services, Inc.	AR	Pediatric Physical Therapist	$0	$29.2M
Life Styles Inc.	AR	Case Management Agency	$0	$19.6M
Washington Regional Medical Center	AR	General Acute Care Hospital	$0	$10.9M
Cross Therapy Services, Ltd	AR	Pediatric Occupational Therapist	$0	$5.8M
Medical Associates Of Northwest Arkansas PA	AR	Pediatrics Physician	$0	$5.8M
Oral & Facial Surgery Center PA	AR	Oral and Maxillofacial Surgery (Dentist)	$0	$4.8M
Thomas A. Sarna, Dds PLLC	AR	Oral and Maxillofacial Surgery Clinic/Center	$0	$3.4M
Washington Regional Medical System	AR	Hospitalist Physician	$0	$3.4M
The Therapy Spot,llc	AR	Speech-Language Pathologist	$0	$3.2M

K'anne Arthur — Billing Profile & Reimbursement Data

Sign up for K'anne Arthur — Billing Profile & Reimbursement Data policy alerts

K'anne Arthur — Billing Profile & Reimbursement Data

Sign up for K'anne Arthur — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References